Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.51 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.51 |
| ▸ | ITGAV | P06756 | 1/20 | 0.51 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.51 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8065362 | 1.00 | ALDH1A1 (0.62) | ALDH1A1MEP1BSIGMAR1ITGB3ITGB1 | |
| SCHEMBL29060375 | 1.00 | ALDH1A1 (0.62) | ALDH1A1MEP1BSIGMAR1ITGB3ITGB1 | |
| Hydrochloric Acid SCHEMBL28019583 | 0.98 | ALDH1A1 (0.60) | ALDH1A1MEP1BSIGMAR1ITGB3ITGB1 | |
| SCHEMBL27719676 | 0.91 | ALDH1A1 (0.54) | ALDH1A1MEP1BSIGMAR1ITGB3ITGB1 | |
| SCHEMBL8161047 | 0.90 | ADAMTS4 (0.54) | ALDH1A1ITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL8093317 | 0.89 | ALDH1A1 (0.54) | ALDH1A1MEP1BSIGMAR1ITGB3ITGB1 | |
| SCHEMBL27853244 | 0.88 | ALDH1A1 (0.51) | ALDH1A1SIGMAR1TSHRKMT2AMEN1 | |
| SCHEMBL5085491 | 0.88 | ALDH1A1 (0.51) | ALDH1A1SIGMAR1TSHRKMT2AMEN1 | |
| SCHEMBL5087907 | 0.88 | ALDH1A1 (0.51) | ALDH1A1SIGMAR1TSHRKMT2AMEN1 | |
| SCHEMBL31336702 | 0.87 | ALDH1A1 (0.53) | ALDH1A1SIGMAR1KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116670143-A | Modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2022-11-10 | — | — | US | disclosed |
| CN-111848727-B | Preparation, activity and application of theanyl tetrahydroimidazopyridine-6-formyl nonpolar amino acid | 首都医科大学 | 2022-04-22 | — | — | CN | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| CN-107698660-B | imidazopyridine-6-formyl-Lys (Lys) -oligopeptides, their synthesis, activity and uses | 首都医科大学 | 2021-06-08 | — | — | CN | disclosed |
| CN-108779098-B | Therapeutic compounds | 希四克斯探索有限公司 | 2021-04-09 | — | — | CN | disclosed |
| CN-106349332-B | imidazopyridinyl-KRGDV, its synthesis, antithrombotic activity and use | 首都医科大学 | 2019-12-10 | — | — | CN | disclosed |
| CN-110062753-A | Antiviral compounds | 哈普洛根有限责任公司 | 2019-07-26 | — | — | CN | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| EP-3512836-A1 | ANTIVIRAL COMPOUNDS | Haplogen GmbH (AT) | 2019-07-24 | — | — | EP | disclosed |
| CN-106366033-B | A kind of double type structure supermolecular gel factor and preparation method thereof | 南京理工大学 | 2019-05-07 | — | — | CN | disclosed |
| WO-2018050631-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2018-03-22 | — | — | WO | disclosed |
| WO-1999010365-A2 | 5',5'-LINKED OLIGOMERS HAVING ANTI-THROMBIN ACTIVITY | GILEAD SCIENCES, INC. (US) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | PLA2G1B, PLA2G12A, PLA2G4C | ALDH1A1 2271/4885MEP1B 2015/4885SIGMAR1 1966/4885 |
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | PLA2G12A, PLA2G1B, PLA2G4C | ALDH1A1 2673/4885MEP1B 1554/4885SIGMAR1 2229/4885 |
| US-11091428-B2 | Antiviral compounds | PLA2G1B, PLA2G12A, PLA2G4C | ALDH1A1 2271/4885MEP1B 2015/4885SIGMAR1 1966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.